ALX Oncology (ALXO) said Friday that data from its ongoing phase 1/2 trial of its evorpacept investigational drug in combination with rituximab and lenalidomide in patients with indolent and aggressive relapsed or refractory B-cell non-Hodgkin lymphoma showed anti-tumor activity.
A median follow-up of 28 months on the patients revealed that the two-year progression-free survival rate was 69% and the two-year overall survival rate was 84%, while 80% achieved complete responses, the company said.
The complete response rate was higher than that of patients who received the standard-of-care rituximab and lenalidomide treatment, the company said.
The phase 2 portion of the study in patients with previously untreated indolent non-Hodgkin lymphoma is ongoing and has completed enrollment, the company added.
Shares of the company were down 9.3% in recent Friday trading.
Price: 0.55, Change: -0.06, Percent Change: -9.32
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。